[go: up one dir, main page]

GT200300240A - Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos - Google Patents

Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos

Info

Publication number
GT200300240A
GT200300240A GT200300240A GT200300240A GT200300240A GT 200300240 A GT200300240 A GT 200300240A GT 200300240 A GT200300240 A GT 200300240A GT 200300240 A GT200300240 A GT 200300240A GT 200300240 A GT200300240 A GT 200300240A
Authority
GT
Guatemala
Prior art keywords
dihydropirimido
pyrimidinone
amino
replaced
manufacture
Prior art date
Application number
GT200300240A
Other languages
English (en)
Inventor
Jianping Cai
Nikolaos Dimoudis
Konrad Honold
Kin-Chun Luk
Stefan Scheiblich
Hilke Sudergat
Georg Tiefenthaler
Oliver Tonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300240A publication Critical patent/GT200300240A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL I EN LA QUE A,R1,R2,R3,R4,N, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON INHIBIDORES DE PROTEINOQUINASAS POR LO QUE SON DE UTILIDAD EN UNA AMPLIA VARIDEAD DE PATOLOGIAS TALES COMO PRINCIPIOS ACTIVOS PARA LA PREVENCION DE RECHAZOS DE TRANSPLANTES, ARTRITIS REUMATOIDE, PSORIASIS, ENTRE OTRAS, DESCRITAS EN LA SOLICITUD.
GT200300240A 2002-11-04 2003-11-03 Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos GT200300240A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02024573 2002-11-04

Publications (1)

Publication Number Publication Date
GT200300240A true GT200300240A (es) 2004-09-02

Family

ID=32116230

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300240A GT200300240A (es) 2002-11-04 2003-11-03 Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos

Country Status (18)

Country Link
US (1) US7091345B2 (es)
EP (1) EP1560831A1 (es)
JP (1) JP2006506408A (es)
KR (1) KR100755770B1 (es)
CN (1) CN1711265A (es)
AR (1) AR041740A1 (es)
AU (1) AU2003287982A1 (es)
BR (1) BR0315988A (es)
CA (1) CA2502477A1 (es)
GT (1) GT200300240A (es)
MX (1) MXPA05004212A (es)
PA (1) PA8587101A1 (es)
PE (1) PE20040593A1 (es)
PL (1) PL377239A1 (es)
RU (1) RU2005117342A (es)
TW (1) TW200413381A (es)
UY (1) UY28059A1 (es)
WO (1) WO2004041823A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100850812B1 (ko) * 2000-10-23 2008-08-06 스미스클라인 비참 코포레이션 신규 화합물
CN1860118A (zh) * 2003-07-29 2006-11-08 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
DE602005013248D1 (de) * 2004-08-31 2009-04-23 Hoffmann La Roche Amidderivate von 3-phenyldihydropyrimidoä4,5-düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel
MX2007002089A (es) * 2004-08-31 2007-03-29 Hoffmann La Roche Derivados de amida de 7-amino-3-fenil-dihidropirimido[4,5-d]pirimidonas, su fabricacion y su uso como inhibidores de proteina cinasa.
AU2006229995A1 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
PE20061351A1 (es) * 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
ATE439361T1 (de) 2006-01-31 2009-08-15 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
US7939557B2 (en) * 2006-04-20 2011-05-10 Nova Southeastern University Vascular endothelial receptor specific inhibitors
BRPI0711628A2 (pt) * 2006-05-15 2011-12-06 Irm Llc composto, composição farmacêutica, uso e processo para preparação do composto
US8436004B2 (en) * 2007-06-15 2013-05-07 Msd K.K. Bicycloaniline derivative
TW200938542A (en) 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
AU2009325400A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
WO2010067886A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
US8722692B2 (en) 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
SG11201507478VA (en) 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108815167B (zh) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 一种化合物在制备治疗肿瘤的药物中的用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313611A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3203308A1 (de) 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate
DE3365492D1 (en) 1982-01-27 1986-10-02 Schering Ag Diphosphonic acid derivatives and pharmaceutical preparations containing them
EP0084822B1 (de) 1982-01-27 1986-01-08 Schering Aktiengesellschaft Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4687768A (en) 1984-12-21 1987-08-18 The Procter & Gamble Company Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism
WO1994009017A1 (en) 1992-10-09 1994-04-28 The Upjohn Company Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
SE9402001D0 (sv) 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
EE200000706A (et) 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
EP1123295B1 (en) 1998-10-23 2004-09-29 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
CZ20021744A3 (cs) 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy
EP1226144B1 (en) 1999-10-21 2006-12-27 F. Hoffmann-La Roche Ag Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles

Also Published As

Publication number Publication date
PA8587101A1 (es) 2004-09-16
AU2003287982A1 (en) 2004-06-07
TW200413381A (en) 2004-08-01
WO2004041823A1 (en) 2004-05-21
CA2502477A1 (en) 2004-05-21
PL377239A1 (pl) 2006-01-23
EP1560831A1 (en) 2005-08-10
KR20050067433A (ko) 2005-07-01
US7091345B2 (en) 2006-08-15
KR100755770B1 (ko) 2007-09-05
CN1711265A (zh) 2005-12-21
US20040087600A1 (en) 2004-05-06
RU2005117342A (ru) 2006-01-20
JP2006506408A (ja) 2006-02-23
PE20040593A1 (es) 2004-09-09
MXPA05004212A (es) 2005-06-08
AR041740A1 (es) 2005-05-26
UY28059A1 (es) 2004-04-30
BR0315988A (pt) 2005-09-20

Similar Documents

Publication Publication Date Title
GT200300240A (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
GT200300138A (es) Moduladores del receptor de glucocorticoides
PA8606901A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CL2011000009A1 (es) Composicion farmaceutica que comprende un compuesto derivado de (diaza)- u (oxa-aza)-biciclo-octano en combinacion con un antibiotico de beta-lactamina; y el uso de la composicion para inhibir la produccion de beta-lactamasa en una terapia antibacteriana. (divisional de la solicitud 134-2003)
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
ES2175624T3 (es) Derivados de pirazolo(4,3-d)pirimidina y composiciones farmaceuticas que los contienen.
GT200300201A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
BRPI0512988A (pt) método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
UY28514A1 (es) Nuevos compuestos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
GT200100160A (es) Derivados 4-fenil-piridina.
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
ECSP045255A (es) Cumarinas utiles como biomarcadores
GT200300028A (es) Derivados iii de dihidrobenzodiacepina-2-ona
GT200300187A (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
GT200200253A (es) Heteroaril nitrilos
PA8589801A1 (es) Aminoalcoxiindoles